BACKGROUND: Cabozantinib can enhance the effect of abiraterone in preclinical prostate cancer models. This study aimed to define the recommended phase 2 dose (RP2D) and preliminary efficacy of abiraterone + cabozantinib in mCRPC. METHODS: Patients with progressive mCRPC with 0-2 prior chemotherapy regimens but no prior CYP17A1 or MET inhibitor received abiraterone acetate at 1000 mg daily with prednisone 5 mg BID in combination with cabozantinib at 20, 40, or 60 mg daily in a dose-escalation 3 + 3 open-label phase 1 design (Part A). After tolerable doses were defined, cohorts were expanded to better define toxicity and efficacy (Part B). RESULTS: There were no dose-limiting toxicities (DLTs) in the first 4 weeks at any of the three dose levels in Part A. Two of the three patients at the 60 mg dose level required dose reductions beyond cycle 2 due to fatigue. In Part B, nine more patients were accrued to each of the 20 and 40 mg doses. Of the 12 patients treated at the 40 mg dose, only one DLT (grade 3 Lipase elevation) was observed in cycle 1. The median time to radiographic progression was 12.88 months (95% CI:5.42- not estimated [NE]) in the 20 mg cohort and 22.01 months (95% CI:15.44-NE) in the 40 mg cohort. Median overall survival was 23.29 months (95% CI:19.06-NE) in the 20 mg cohort and 39.08 months (95% CI:17.38-NE) in the 40 mg cohort. CONCLUSIONS: Based on tolerability and preliminary efficacy, 40 mg cabozantinib plus 1000 mg abiraterone daily is the RP2D.
BACKGROUND:Cabozantinib can enhance the effect of abiraterone in preclinical prostate cancer models. This study aimed to define the recommended phase 2 dose (RP2D) and preliminary efficacy of abiraterone + cabozantinib in mCRPC. METHODS:Patients with progressive mCRPC with 0-2 prior chemotherapy regimens but no prior CYP17A1 or MET inhibitor received abiraterone acetate at 1000 mg daily with prednisone 5 mg BID in combination with cabozantinib at 20, 40, or 60 mg daily in a dose-escalation 3 + 3 open-label phase 1 design (Part A). After tolerable doses were defined, cohorts were expanded to better define toxicity and efficacy (Part B). RESULTS: There were no dose-limiting toxicities (DLTs) in the first 4 weeks at any of the three dose levels in Part A. Two of the three patients at the 60 mg dose level required dose reductions beyond cycle 2 due to fatigue. In Part B, nine more patients were accrued to each of the 20 and 40 mg doses. Of the 12 patients treated at the 40 mg dose, only one DLT (grade 3 Lipase elevation) was observed in cycle 1. The median time to radiographic progression was 12.88 months (95% CI:5.42- not estimated [NE]) in the 20 mg cohort and 22.01 months (95% CI:15.44-NE) in the 40 mg cohort. Median overall survival was 23.29 months (95% CI:19.06-NE) in the 20 mg cohort and 39.08 months (95% CI:17.38-NE) in the 40 mg cohort. CONCLUSIONS: Based on tolerability and preliminary efficacy, 40 mg cabozantinib plus 1000 mg abiraterone daily is the RP2D.
Authors: Toni K Choueiri; Bernard Escudier; Thomas Powles; Nizar M Tannir; Paul N Mainwaring; Brian I Rini; Hans J Hammers; Frede Donskov; Bruce J Roth; Katriina Peltola; Jae Lyun Lee; Daniel Y C Heng; Manuela Schmidinger; Neeraj Agarwal; Cora N Sternberg; David F McDermott; Dana T Aftab; Colin Hessel; Christian Scheffold; Gisela Schwab; Thomas E Hutson; Sumanta Pal; Robert J Motzer Journal: Lancet Oncol Date: 2016-06-05 Impact factor: 41.316
Authors: Ethan Basch; Karen A Autio; Matthew R Smith; Antonia V Bennett; Aaron L Weitzman; Christian Scheffold; Christopher Sweeney; Dana E Rathkopf; David C Smith; Daniel J George; Celestia S Higano; Andrea L Harzstark; A Oliver Sartor; Michael S Gordon; Nicholas J Vogelzang; Johann S de Bono; Naomi B Haas; Paul G Corn; Frauke Schimmoller; Howard I Scher Journal: Eur Urol Date: 2014-02-20 Impact factor: 20.096
Authors: Mary-Ellen Taplin; Bruce Montgomery; Christopher J Logothetis; Glenn J Bubley; Jerome P Richie; Bruce L Dalkin; Martin G Sanda; John W Davis; Massimo Loda; Lawrence D True; Patricia Troncoso; Huihui Ye; Rosina T Lis; Brett T Marck; Alvin M Matsumoto; Steven P Balk; Elahe A Mostaghel; Trevor M Penning; Peter S Nelson; Wanling Xie; Zhenyang Jiang; Christopher M Haqq; Daniel Tamae; NamPhuong Tran; Weimin Peng; Thian Kheoh; Arturo Molina; Philip W Kantoff Journal: J Clin Oncol Date: 2014-10-13 Impact factor: 44.544
Authors: Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher Journal: N Engl J Med Date: 2011-05-26 Impact factor: 91.245
Authors: Richard J Lee; Philip J Saylor; M Dror Michaelson; S Michael Rothenberg; Malgorzata E Smas; David T Miyamoto; Carol A Gurski; Wanling Xie; Shyamala Maheswaran; Daniel A Haber; Jonathan G Goldin; Matthew R Smith Journal: Clin Cancer Res Date: 2013-04-03 Impact factor: 12.531
Authors: A O'Donnell; I Judson; M Dowsett; F Raynaud; D Dearnaley; M Mason; S Harland; A Robbins; G Halbert; B Nutley; M Jarman Journal: Br J Cancer Date: 2004-06-14 Impact factor: 7.640
Authors: Daniel Castellano; Andrea B Apolo; Camillo Porta; Jaume Capdevila; Santiago Viteri; Cristina Rodriguez-Antona; Lidia Martin; Pablo Maroto Journal: Ther Adv Med Oncol Date: 2022-07-30 Impact factor: 5.485